drugset
drugset / Trial / NCT00730262

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

NCT00730262 ↗

Phase 2 Terminated 40 enrolled Thallion Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the efficacy and safety of TLN-4601 used to treat patients with Glioblastoma Multiforme(GBM) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.

Timeline

Start
2008-08
Primary completion
2010-04
Completion
2010-06

Outcome

Outcome not reported

Stopped: “Lack of efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject DIAZEPINOMICIN Small molecule 480 mg/m2 Intravenous

Indications

glioblastoma